Dr Christopher Rowe
Conjoint Senior Lecturer
School of Medicine and Public Health
Career Summary
Biography
I am an Adult Endocrinologist (FRACP), with practice at John Hunter Hospital and at Newcastle Endocrinology.
I have trained in Sydney and Newcastle, and completed a visiting fellowship at the University of Birmingham and Queen Elizabeth Hospital.
My PhD examined the role of neurotrophins in thyroid cancer, and we were the first to show that thyroid cancer is innervated.
In addition, our group is examining the utility of the TSH receptor as a specific theranostic marker for drug delivery, in collaboration with the John Hunter Hospital Thyroid Cancer Multidisciplinary Team, the Hunter Cancer Biobank and Pathology North (Hunter). I am also collaborating with Professor Hubert Hondermarck in the School of Biomedical Sciences and Pharmacy to study the role of neurotrophins as biomarkers and therapeutic targets in thyroid malignancy.
I am active in a number of clinical research projects studying the impact of visceral fat on insulin resistance in Type 1 Diabetes, and management of diabetes in pregnancy.
I am an inaugural recipient of a Clinical Research Fellowship (Hunter New England Local Health District), and my recent research has been supported by the Hunter Cancer Research Alliance, Avant Mutual Group, the University of Newcastle, and the John Hunter Hospital Charitable Trust.
Qualifications
- Bachelor of Medicine, Bachelor of Surgery (Hons), University of New South Wales
- Bachelor of Science (Medicine), University of New South Wales
Keywords
- Diabetes Mellitus
- endocrinology
- insulin resistance
- pregnancy
- thyroid
Awards
Prize
Year | Award |
---|---|
2019 |
ADIPS Outstanding Abstract Award (Travel Grant) Australasian Diabetes in Pregnancy Society |
2016 |
Australian Diabetes Society Travel Grant (Outstanding Abstract) Australian Diabetes Society (ADS) |
2016 |
Australasian Diabetes in Pregnancy Society Travel Grant (Outstanding Abstract) Australian Diabetes in Pregnancy Society (ADIPS) |
2015 |
Endocrine Society (USA) Travel Grant (Outstanding Abstract) The Endocrine Society |
Invitations
Speaker
Year | Title / Rationale |
---|---|
2019 |
Maternal hyperglycaemia and neonatal hypoglycaemia following betamethasone can be safely reduced by a pregnancy-specific algorithm-driven intravenous insulin infusion in women with gestational diabetes Administering betamethasone to women with gestational diabetes causes maternal hyperglycaemia, and is associated with neonatal hypoglycaemia 1. There are limited data to guide interventions to control maternal hyperglycaemia in this population, including treatment targets and endpoints. Here we discuss results of a recently published cohort study 2 reporting safety and efficacy of a novel Pregnancy-specific Intravenous Insulin-Glucose Infusion (P-IVI) protocol, validated at John Hunter Hospital since 2017, as compared to the previous standard of care (a generic Adult IntraVenous Insulin protocol (A-IVI) not designed for pregnancy). Primary outcome was percentage of on-infusion time with capillary blood glucose (BGL) at target (3.8-7mmol/L). Secondary outcomes were percentage time with critical hyperglycaemia (BGL>10mmol/L) or hypoglycaemia (BGL <3.8mmol/L), and incidence of neonatal hypoglycaemia (BGL<2.5mmol/L in first 48 hours if betamethasone given within 2 days of birth). We found that on-infusion time at target was 68% (95%CI 64-71%) for P-IVI compared to 55% (95%CI 50-60%) for AIVI (p=0.0002). Time with critical hyperglycaemia was lower with P-IVI compared to A-IVI (0% vs 2%, p=0.02), with lower incidence of maternal hypoglycaemia (2% vs 12%, p=0.02). Neonatal hypoglycaemia occurred in 29% of births following P-IVI, compared to 54% births following A-IVI (p=0.03). A multiple logistic regression model adjusting for potential confounders gave an odds ratio for neonatal hypoglycaemia with P-IVI of 0.27 (95%CI 0.10-0.76, p=0.01). We conclude that an infusion protocol designed for pregnancy effectively controlled maternal hyperglycaemia following betamethasone. This is the first protocol to show a reduction in betamethasone-associated neonatal hypoglycaemia, linked with optimum maternal glycaemic control.
|
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Chapter (2 outputs)
Year | Citation | Altmetrics | Link | |||||
---|---|---|---|---|---|---|---|---|
2022 | Rowe C, Boelaert K, 'Thyroid Nodules and Thyroid Cancer Prior To, During, and Following Pregnancy', Endotext [Internet], ENDOTEXT, Internet (2022) | |||||||
2020 |
Rowe C, Boelaert K, Smith R, 'Thyroid Cancer During Pregnancy and Lactation', Maternal-Fetal and Neonatal Endocrinology: Physiology, Pathophysiology, and Clinical Management, Academic Press: Elsevier, London, UK 317-327 (2020) [B1]
|
Nova |
Journal article (30 outputs)
Year | Citation | Altmetrics | Link | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2024 |
Rowe CW, Rosee P, Sathiakumar A, Ramesh S, Qiao V, Huynh J, et al., 'Factors associated with maternal hyperglycaemia and neonatal hypoglycaemia after antenatal betamethasone administration in women with diabetes in pregnancy.', Diabet Med, 41 e15262 (2024) [C1]
|
||||||||||
2023 |
Wadsley J, Balasubramanian SP, Madani G, Munday J, Roques T, Rowe CW, et al., 'Consensus statement on the management of incidentally discovered FDG avid thyroid nodules in patients being investigated for other cancers.', Clin Endocrinol (Oxf), (2023) [C1]
|
||||||||||
2023 |
O'Neill CJ, Carlson MA, Rowe CW, Fradgley EA, Paul C, 'Hearing the Voices of Australian Thyroid Cancer Survivors: Qualitative Thematic Analysis of Semistructured Interviews Identifies Unmet Support Needs.', Thyroid : official journal of the American Thyroid Association, 33 1455-1464 (2023) [C1]
|
Nova | |||||||||
2023 |
Widjaja W, Rowe CW, Oldmeadow C, Cope D, Fradgley EA, Paul C, O'Neill CJ, 'Current patterns of care in low-risk thyroid cancer-A national cross-sectional survey of Australian thyroid clinicians.', Endocrinol Diabetes Metab, 6 e398 (2023) [C1]
|
Nova | |||||||||
2023 |
Rowe CW, Qiao V, Ramesh S, Rosee P, Sathiakumar A, McWhae-Brown S, et al., 'Adoption of a pregnancy-specific intravenous insulin protocol (Pregnancy-IVI) at a regional centre has equivalent safety and efficacy outcomes as a tertiary hospital', Diabetic Medicine, 40 (2023) [C1]
|
Nova | |||||||||
2023 |
O'Neill CJ, Morris-Baguley H, Alam AS, Carlson MA, Blefari N, Rowe CW, et al., 'Thyroid cancer patient reported outcome measures in clinical practice: analysing acceptability and optimizing recruitment.', ANZ J Surg, 93 2214-2221 (2023) [C1]
|
Nova | |||||||||
2022 |
Astono IP, Welsh JS, Rowe CW, Jobling P, 'Objective quantification of nerves in immunohistochemistry specimens of thyroid cancer utilising deep learning.', PLoS Comput Biol, 18 e1009912 (2022) [C1]
|
Nova | |||||||||
2022 |
Blefari NDA, Rowe CW, Wiadji E, Lambkin D, Carroll R, Fradgley EA, O'Neill CJ, 'Long-Term Health-Related Quality of Life Outcomes Following Thyroid Surgery for Malignant or Benign Disease: Deficits Persist in Cancer Survivors Beyond Five Years.', World J Surg, 46 2423-2432 (2022) [C1]
|
Nova | |||||||||
2021 |
Rowe CW, Watkins B, Brown K, Delbridge M, Addley J, Woods A, Wynne K, 'Efficacy and safety of the pregnancy-IVI, an intravenous insulin protocol for pregnancy, following antenatal betamethasone in type 1 and type 2 diabetes', Diabetic Medicine, 38 (2021) [C1] Aims: Hyperglycaemia following antenatal corticosteroids is common in women with diabetes in pregnancy, and validated algorithms to maintain pregnancy-specific glucose targets are... [more] Aims: Hyperglycaemia following antenatal corticosteroids is common in women with diabetes in pregnancy, and validated algorithms to maintain pregnancy-specific glucose targets are lacking. The Pregnancy-IVI, an intravenous-insulin (IVI) algorithm, has been validated in gestational diabetes; however, its performance in pre-existing diabetes (Type 1 and Type 2 diabetes) is not known. We hypothesised that Pregnancy-IVI would be superior to a generic Adult-IVI protocol (prior standard of care) following betamethasone in women with pre-existing diabetes. Methods: A retrospective cohort study enrolled all women with pre-existing diabetes at a tertiary centre receiving betamethasone and treated with IVI according to one of two protocols: Adult-IVI (n¿=¿73, 2014¿2017) or Pregnancy-IVI (n¿=¿62, 2017¿2020). The primary outcome was on-IVI glycaemic time-in-range (capillary blood glucose (BGL) 3.8¿7.0¿mmol/L). Secondary outcomes included time with critical hyperglycaemia (BGL¿>¿10¿mmol/L); occurrence of maternal hypoglycaemia (BGL¿<¿3.8¿mmol/l) and incidence of neonatal hypoglycaemia (BGL¿=¿2.5¿mmol/L). Analysis was stratified by diabetes type. Results: Overall, Pregnancy-IVI achieved a higher proportion of on-IVI time-in-range (70%, IQR 56¿78%) compared to Adult-IVI (52%, IQR 41¿69%, p¿<¿0.0001). The duration of critical hyperglycaemia with Pregnancy-IVI was also reduced (2% [IQR 0¿7] vs 8% [IQR 4¿17], p¿<¿0.0001), without an increase in hypoglycaemia. Glycaemic variability was significantly reduced with Pregnancy-IVI. No difference in the rate of neonatal hypoglycaemia was observed. The Pregnancy-IVI was most effective in women with Type 1 diabetes. Conclusion: The Pregnancy-IVI algorithm is safe and effective when used following betamethasone in type 1 diabetes in pregnancy. Further study of women with type 2 diabetes is required.
|
Nova | |||||||||
2021 |
Croker EE, McGrath SA, Rowe CW, 'Thyroid disease: Using diagnostic tools effectively', Australian Journal of General Practice, 50 16-21 (2021) [C1]
|
Nova | |||||||||
2021 |
Fenton ME, Wade SA, Pirrili BN, Balogh ZJ, Rowe CW, Bendinelli C, 'Variability in thyroid cancer multidisciplinary team meeting recommendations is not explained by standard variables: Outcomes of a single centre review', Journal of Clinical Medicine, 10 (2021) [C1] Multidisciplinary team (MDT) meetings are the mainstay of the decision-making process for patients presenting with complex clinical problems such as papillary thyroid carcinoma (P... [more] Multidisciplinary team (MDT) meetings are the mainstay of the decision-making process for patients presenting with complex clinical problems such as papillary thyroid carcinoma (PTC). Adherence to guidelines by MDTs has been extensively investigated; however, scarce evidence exists on MDT performance and variability where guidelines are less prescriptive. We evaluated the consistency of MDT management recommendations for T1 and T2 PTC patients and explored key variables that may influence therapeutic decision making. A retrospective review of the prospective database of all T1 and T2 PTC patients discussed by the MDT was conducted between January 2016 and May 2021. Univariate analysis (with Bonferroni correction significance calculated at p < 0.006) was performed to establish clinical variables linked to completion thyroidectomy and Radioactive iodine (RAI) recommendations. Of 468 patients presented at thyroid MDT, 144 pT1 PTC and 118 pT2 PTC met the selection criteria. Only 18% (n = 12) of pT1 PTC patients initially managed with hemithyroidectomy were recommended completion thyroidectomy. Mean tumour diameter was the only variable differing between groups (p = 0.003). pT2 patients were recommended completion thyroidectomy in 66% (n = 16) of instances. No measured variable explained the difference in recommendation. pT1 patients initially managed with total thyroidectomy were not recommended RAI in 71% (n = 55) of cases with T1a status (p = 0.001) and diameter (p = 0.001) as statistically different variables. For pT2 patients, 60% (n = 41) were recommended RAI post-total thyroidectomy, with no differences observed among groups. The majority of MDT recommendations were concordant for patients with similar measurable characteristics. Discordant recommendations for a small group of patients were not explained by measured variables and may have been accounted for by individual patient factors. Further research into the MDT decision-making process is warranted.
|
Nova | |||||||||
2020 |
Griffin N, Rowe CW, Gao F, Jobling P, Wills V, Walker MM, et al., 'Clinicopathological Significance of Nerves in Esophageal Cancer', American Journal of Pathology, 190 1921-1930 (2020) [C1] Nerves are emerging promoters of cancer progression, but the innervation of esophageal cancer and its clinicopathologic significance remain unclear. In this study, nerves were ana... [more] Nerves are emerging promoters of cancer progression, but the innervation of esophageal cancer and its clinicopathologic significance remain unclear. In this study, nerves were analyzed by immunohistochemistry in a cohort of 260 esophageal cancers, including 40 matched lymph node metastases and 137 normal adjacent esophageal tissues. Nerves were detected in 38% of esophageal cancers and were more associated with squamous cell carcinomas (P = 0.04). The surrounding or invasion of nerves by cancer cells (perineural invasion) was detected in 12% of esophageal cancers and was associated with reduced survival (P = 0.04). Nerves were found to express the following receptors for nerve growth factor (NGF): neurotrophic receptor tyrosine kinase 1 and nerve growth factor receptor. An association was suggested between high production of NGF by cancer cells and the presence of nerves (P = 0.02). In vitro, NGF production in esophageal cancer cells was shown by Western blot, and esophageal cancer cells were able to induce neurite outgrowth in the PC12 neuronal cells. The neurotrophic activity of esophageal cancer cells was inhibited by anti-NGF blocking antibodies. Together, these data suggest that innervation is a feature in esophageal cancers that may be driven by cancer cell¿released NGF.
|
Nova | |||||||||
2020 |
Faulkner S, Griffin N, Rowe CW, Jobling P, Lombard JM, Oliveira SM, et al., 'Nerve growth factor and its receptor tyrosine kinase TrkA are overexpressed in cervical squamous cell carcinoma.', FASEB bioAdvances, 2 398-408 (2020) [C1]
|
Nova | |||||||||
2020 |
Wynne K, Rowe C, Delbridge M, Watkins B, Brown K, Addley J, et al., 'Antenatal corticosteroid administration for foetal lung maturation', F1000Research, 9 1-12 (2020) [C1]
|
Nova | |||||||||
2020 |
Rowe CW, Dill T, Griffin N, Jobling P, Faulkner S, Paul JW, et al., 'Innervation of papillary thyroid cancer and its association with extra-thyroidal invasion', Scientific Reports, 10 (2020) [C1]
|
Nova | |||||||||
2019 |
Rowe CW, Arthurs S, O Neill CJ, Hawthorne J, Carroll R, Wynne K, Bendinelli C, 'High-dose preoperative cholecalciferol to prevent post-thyroidectomy hypocalcaemia: A randomized, double-blinded placebo-controlled trial', Clinical Endocrinology, 90 343-350 (2019) [C1] Objective: Post-thyroidectomy hypocalcaemia is a significant cause of morbidity and prolonged hospitalization, usually due to transient parathyroid gland damage, treated with calc... [more] Objective: Post-thyroidectomy hypocalcaemia is a significant cause of morbidity and prolonged hospitalization, usually due to transient parathyroid gland damage, treated with calcium and vitamin D supplementation. We present a randomized, double-blinded placebo-controlled trial of preoperative loading with high-dose cholecalciferol (300¿000 IU) to reduce post-thyroidectomy hypocalcaemia. Patients and Measurements: Patients (n¿=¿160) presenting for thyroidectomy at tertiary hospitals were randomized 1:1 to cholecalciferol (300¿000¿IU) or placebo 7¿days prior to thyroidectomy. Ten patients withdrew prior to surgery. The primary outcome was post-operative hypocalcaemia (corrected calcium <2.1¿mmol/L in first 180¿days). Results: The study included 150 patients undergoing thyroidectomy for Graves¿ disease (31%), malignancy (20%) and goitre (49%). Mean pre-enrolment vitamin D was 72¿±¿26¿nmol/L. Postoperative hypocalcaemia occurred in 21/72 (29%) assigned to cholecalciferol and 30/78 (38%) participants assigned to placebo (P¿=¿0.23). There were no differences in secondary end-points between groups. In pre-specified stratification, baseline vitamin D status did not predict hypocalcaemia, although most individuals were vitamin D replete at baseline. Post-hoc stratification by day 1 parathyroid hormone (PTH) (<10¿pg/mL, low vs =10¿pg/mL, normal) was explored due to highly divergent rates of hypocalcaemia in these groups. Using a Cox regression model, the hazard ratio for hypocalcaemia in the cholecalciferol group was 0.56 (95%CI 0.32-0.98, P¿=¿0.04) after stratification for Day 1 PTH. Further clinical benefits were observed in these subgroups. Conclusions: Pre-thyroidectomy treatment with high-dose cholecalciferol did not reduce the overall rate of hypocalcaemia following thyroidectomy. In subgroups stratified by day 1 PTH status, improved clinical outcomes were noted.
|
Nova | |||||||||
2019 |
Rowe CW, Faulkner S, Paul JW, Tolosa JM, Gedye C, Bendinelli C, et al., 'The precursor for nerve growth factor (proNGF) is not a serum or biopsy-rinse biomarker for thyroid cancer diagnosis.', BMC endocrine disorders, 19 128 (2019) [C1]
|
Nova | |||||||||
2019 |
Rowe CW, Dill T, Faulkner S, Gedye C, Paul JW, Tolosa JM, et al., 'The precursor for nerve growth factor (ProNGF) in thyroid cancer lymph node metastases: Correlation with primary tumour and pathological variables', International Journal of Molecular Sciences, 20 1-13 (2019) [C1]
|
Nova | |||||||||
2019 |
Rowe CW, Putt E, Brentnall O, Gebuehr A, Allabyrne J, Woods A, Wynne K, 'An intravenous insulin protocol designed for pregnancy reduces neonatal hypoglycaemia following betamethasone administration in women with gestational diabetes', Diabetic Medicine, 36 228-236 (2019) [C1] Aims: Marked hyperglycaemia is common following betamethasone administration in women with gestational diabetes (GDM), and may contribute to neonatal hypoglycaemia. Validated prot... [more] Aims: Marked hyperglycaemia is common following betamethasone administration in women with gestational diabetes (GDM), and may contribute to neonatal hypoglycaemia. Validated protocols to deliver glycaemic stability following betamethasone are lacking. We hypothesized that an intravenous insulin (IVI) protocol for pregnancy-specific glycaemic targets (Pregnancy-IVI) would achieve greater at-target glycaemic control than a generic adult intravenous insulin protocol (Adult-IVI), and may reduce neonatal hypoglycaemia. Methods: A retrospective cohort study of the performance Adult-IVI and Pregnancy-IVI following betamethasone in GDM, sequentially implemented at a tertiary hospital, without change in indication for IVI. Cases were identified by electronic record search. Primary outcome was percentage of on-IVI time with at-target glycaemia [blood glucose level (BGL) 3.8¿7¿mmol/l]. Secondary outcomes were time with critical hyperglycaemia (BGL >¿10¿mmol/l), occurrence of maternal hypoglycaemia (BGL <¿3.8¿mmol/l), and incidence of neonatal hypoglycaemia (BGL =¿2.5¿mmol/l) if betamethasone was administered within 48¿h of birth. Results: The cohorts comprised 151 women (Adult-IVI n¿=¿86; Pregnancy-IVI n¿=¿65). The primary outcome was 68% time-at-target [95% confidence interval (CI) 64¿71%) for Pregnancy-IVI compared with 55% (95% CI 50¿60%) for Adult-IVI (P¿=¿0.0002). Critical maternal hyperglycaemia (0% vs. 2%, P¿=¿0.02) and hypoglycaemia (2% vs. 12%, P¿=¿0.02) were both lower with Pregnancy-IVI than Adult-IVI. Neonatal hypoglycaemia was less common after Pregnancy-IVI (29%) than after Adult-IVI (54%, P¿=¿0.03). A multiple logistic regression model adjusting for potential confounders gave an odds ratio for neonatal hypoglycaemia with Pregnancy-IVI of 0.27 (95% CI 0.10¿0.76, P¿=¿0.01). Conclusions: An IVI protocol designed for pregnancy effectively controlled maternal hyperglycaemia following betamethasone administration in GDM. This is the first intervention to show a reduction in betamethasone-associated neonatal hypoglycaemia, linked with optimum maternal glycaemic control.
|
Nova | |||||||||
2019 |
Marlow AL, Rowe CW, Anderson D, Wynne K, King BR, Howley P, Smart CE, 'Young children, adolescent girls and women with type 1 diabetes are more overweight and obese than reference populations, and this is associated with increased cardiovascular risk factors.', Diabetic medicine : a journal of the British Diabetic Association, 36 1487-1493 (2019) [C1]
|
Nova | |||||||||
2018 |
Gao F, Griffin N, Faulkner S, Rowe CW, Williams L, Roselli S, et al., 'The neurotrophic tyrosine kinase receptor TrkA and its ligand NGF are increased in squamous cell carcinomas of the lung', SCIENTIFIC REPORTS, 8 (2018) [C1]
|
Nova | |||||||||
2018 |
Faulkner S, Jobling P, Rowe CW, Rodrigues Oliveira SM, Roselli S, Thorne RF, et al., 'Neurotrophin Receptors TrkA, p75 Neurotrophin receptors are emerging targets in oncology, but their clinicopathologic significance in thyroid cancer is unclear. In this study, the neurotrophin tyrosine receptor k... [more] Neurotrophin receptors are emerging targets in oncology, but their clinicopathologic significance in thyroid cancer is unclear. In this study, the neurotrophin tyrosine receptor kinase TrkA (also called NTRK1), the common neurotrophin receptor p75NTR, and the proneurotrophin receptor sortilin were analyzed with immunohistochemistry in a cohort of thyroid cancers (n = 128) and compared with adenomas and normal thyroid tissues (n = 62). TrkA was detected in 20% of thyroid cancers, compared with none of the benign samples (P = 0.0007). TrkA expression was independent of histologic subtypes but associated with lymph node metastasis (P = 0.0148), suggesting the involvement of TrkA in tumor invasiveness. Nerves in the tumor microenvironment were positive for TrkA. p75NTR was overexpressed in anaplastic thyroid cancers compared with papillary and follicular subtypes (P < 0.0001). Sortilin was overexpressed in thyroid cancers compared with benign thyroid tissues (P < 0.0001). Neurotrophin receptor expression was confirmed in a panel of thyroid cancer cell lines at the mRNA and protein levels. Functional investigations using the anaplastic thyroid cancer cell line CAL-62 found that siRNA against TrkA, p75NTR, and sortilin decreased cell survival and cell migration through decreased SRC and ERK activation. Together, these data reveal TrkA, p75NTR, and sortilin as potential therapeutic targets in thyroid cancer.
|
Nova | |||||||||
2017 |
Rowe CW, Paul JW, Gedye C, Tolosa JM, Bendinelli C, McGrath S, Smith R, 'Targeting the TSH receptor in thyroid cancer', Endocrine-Related Cancer, 24 R191-R202 (2017) [C1] Recent advances in the arena of theranostics have necessitated a re-examining of previously established fields. The existing paradigm of therapeutic thyroid-stimulating hormone re... [more] Recent advances in the arena of theranostics have necessitated a re-examining of previously established fields. The existing paradigm of therapeutic thyroid-stimulating hormone receptor (TSHR) targeting in the post-surgical management of differentiated thyroid cancer using levothyroxine and recombinant human thyroid-stimulating hormone (TSH) is well understood. However, in an era of personalized medicine, and with an increasing awareness of the risk profile of longstanding pharmacological hyperthyroidism, it is imperative clinicians understand the molecular basis and magnitude of benefit for individual patients. Furthermore, TSHR has been recently re-conceived as a selective target for residual metastatic thyroid cancer, with pilot data demonstrating effective targeting of nanoparticles to thyroid cancers using this receptor as a target. This review examines the evidence for TSHR signaling as an oncogenic pathway and assesses the evidence for ongoing TSHR expression in thyroid cancer metastases. Priorities for further research are highlighted.
|
Nova | |||||||||
2017 |
Rowe CW, Haider AS, Viswanathan D, Jones M, Attia J, Wynne K, Acharya S, 'Insulin resistance correlates with maculopathy and severity of retinopathy in young adults with Type 1 Diabetes Mellitus', Diabetes Research and Clinical Practice, 131 154-160 (2017) [C1] Aims To assess the relationship between insulin resistance (IR), retinopathy and maculopathy in young adults with Type 1 diabetes mellitus. Methods A cross-sectional study at a re... [more] Aims To assess the relationship between insulin resistance (IR), retinopathy and maculopathy in young adults with Type 1 diabetes mellitus. Methods A cross-sectional study at a regional Australian tertiary hospital. Retinal pathology, assessed by colour fundus photography, was correlated with two surrogate measures of IR: estimated Glucose Disposal Rate (eGDR) and Insulin Sensitivity Score (ISS), where lower scores reflect greater IR. Results 107 patients were recruited, with mean age 24.7¿years, 53% male, and mean duration of disease 10.8¿years. Mean eGDR scores (5.6¿vs 8.0 p¿<¿0.001) and ISS (4.7¿vs 7.9, p¿<¿0.001) were lower in subjects having at least moderate non-proliferative diabetic retinopathy (NPDR; relative to nil/mild-NPDR). Similarly, mean eGDR (4.2¿vs 6.2, p¿=¿0.001) and ISS (3.8¿vs 6.1, p¿=¿0.003) were lower in patients with maculopathy. Multivariate logistic regression modelling was used to control for confounding. For retinopathy severity, a unit increase in eGDR or ISS (representing lower IR) was associated with a 50% decrease in odds of moderate-NPDR or worse (eGDR OR 0.5, 95%CI 0.32¿0.77, p¿=¿0.002; ISS OR 0.49, 95%CI 0.29¿0.84, p¿=¿0.01). A unit increase in eGDR or ISS was associated with a 46¿56% decrease in odds of maculopathy (eGDR OR 0.54, 95%CI 0.37¿0.81, p¿=¿0.003; ISS OR 0.44, 95%CI 0.22¿0.88, p¿=¿0.02). Conclusions IR correlates with more severe retinopathy in young adults with Type 1¿DM. This is the first description of a correlation between IR and maculopathy in Type 1¿DM, warranting further evaluation. Prospective studies examining whether reducing IR can improve microvascular complications are required.
|
Nova | |||||||||
Show 27 more journal articles |
Conference (32 outputs)
Year | Citation | Altmetrics | Link | |||||
---|---|---|---|---|---|---|---|---|
2021 |
Croker E, Mohammad N, Rowe C, Wynne K, 'Accuracy of continuous glucose monitoring during periods of predicted acute glycaemic variability in pregnancy in women with Type 1 Diabetes Mellitus in the inpatient setting: A pilot study', Virtual (2021)
|
|||||||
2021 | Yu W, Rowe C, 'GnRH-ating a puzzle', Virtual (2021) | |||||||
2021 |
Hampton J, Wiadji E, Rowe C, Fradgley E, Cope D, Paul C, O'Neill C, 'Follow-up of Patients with Low-Risk Thyroid Cancer: a Survey of Clinician Preferences.', Melbourne (2021)
|
|||||||
Show 29 more conferences |
Preprint (5 outputs)
Year | Citation | Altmetrics | Link | ||
---|---|---|---|---|---|
2019 |
Rowe CW, Faulkner S, Paul JW, Tolosa JM, Gedye C, Bendinelli C, et al., 'The precursor for nerve growth factor (proNGF) is not a serum or biopsy-rinse biomarker for thyroid cancer diagnosis (2019)
|
||||
2019 |
Rowe CW, Faulkner S, Paul JW, Tolosa JM, Gedye C, Bendinelli C, et al., 'The precursor for nerve growth factor (proNGF) is not a serum or biopsy-rinse biomarker for thyroid cancer diagnosis (2019)
|
||||
2019 |
Rowe CW, Faulkner S, Paul JW, Tolosa JM, Gedye C, Bendinelli C, et al., 'The precursor for nerve growth factor (proNGF) is not a serum or biopsy-rinse biomarker for thyroid cancer diagnosis (2019)
|
||||
Show 2 more preprints |
Grants and Funding
Summary
Number of grants | 11 |
---|---|
Total funding | $1,263,678 |
Click on a grant title below to expand the full details for that specific grant.
20231 grants / $50,000
Empowering patients and clinicians to make shared treatment decisions in low-risk thyroid cancer$50,000
Funding body: NSW Regional Cancer Research Network
Funding body | NSW Regional Cancer Research Network |
---|---|
Project Team | Christine O'Neill, Nick Zdenkowski |
Scheme | ‘Shovel-Ready’ translational research projects |
Role | Investigator |
Funding Start | 2023 |
Funding Finish | 2024 |
GNo | |
Type Of Funding | Other Public Sector - State |
Category | 2OPS |
UON | N |
20221 grants / $10,484
Development of targeted liposomes to localise abnormal endocrine glands$10,484
Funding body: John Hunter Charitable Trust
Funding body | John Hunter Charitable Trust |
---|---|
Scheme | John Hunter Charitable Trust Grant |
Role | Investigator |
Funding Start | 2022 |
Funding Finish | 2022 |
GNo | |
Type Of Funding | Other Public Sector - State |
Category | 2OPS |
UON | N |
20211 grants / $18,182
Controlling high glucose levels after antenatal steroids in women with diabetes in pregnancy$18,182
Funding body: John Hunter Charitable Trust Grant
Funding body | John Hunter Charitable Trust Grant |
---|---|
Project Team | Rowe CW, Mohammad N, Woods A, Wynne K |
Scheme | John Hunter Charitable Trust Grant |
Role | Lead |
Funding Start | 2021 |
Funding Finish | 2023 |
GNo | |
Type Of Funding | Other Public Sector - State |
Category | 2OPS |
UON | N |
20201 grants / $15,000
DIFFICLT study: Dosing Insulin For Food In Closed Loop Therapy in young adults with Type 1 Diabetes$15,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Miss Prudence Lopez, Doctor Christopher Rowe, Doctor Rowen Seckold, Doctor Carmel Smart |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2020 |
Funding Finish | 2020 |
GNo | G2000003 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20192 grants / $33,080
Quality of Life Assessment in Thyroid Cancer – A Pilot Study to Evaluate Quality of Life Assessment Tools $20,918
Funding body: Hunter Cancer Research Alliance (HCRA)
Funding body | Hunter Cancer Research Alliance (HCRA) |
---|---|
Project Team | CJ O'Neill, N Blefari, Rowe CW, Carroll R, Fragdley E |
Scheme | HCRA Implementation Flagship program |
Role | Investigator |
Funding Start | 2019 |
Funding Finish | 2022 |
GNo | |
Type Of Funding | C3112 - Aust Not for profit |
Category | 3112 |
UON | N |
Artificial intelligence (with machine learning) to quantify nerve density in cancer with prognostic and therapeutic potential$12,162
Funding body: John Hunter Charitable Trust Grant
Funding body | John Hunter Charitable Trust Grant |
---|---|
Project Team | CW Rowe, P Jobling, R Vilain, J Welch |
Scheme | John Hunter Charitable Trust Grant |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2023 |
GNo | |
Type Of Funding | Other Public Sector - State |
Category | 2OPS |
UON | N |
20181 grants / $725,684
Hunter Cancer Biobank$725,684
Funding body: NSW Health Pathology - Pathology North
Funding body | NSW Health Pathology - Pathology North |
---|---|
Project Team | Professor Marjorie Walker, Professor Rodney Scott, Conjoint Professor Stephen Ackland, Mrs Susan Goode, Professor Pradeep Tanwar, Associate Professor Nikki Verrills, Professor Hubert Hondermarck, Doctor Simon King, Mr Ricardo Vilain, Professor Nikola Bowden, Associate Professor Kelly Kiejda, Professor Simon Keely, Doctor Christopher Rowe |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2022 |
GNo | G1800704 |
Type Of Funding | C2400 – Aust StateTerritoryLocal – Other |
Category | 2400 |
UON | Y |
20171 grants / $15,000
Hunter Cancer Research Alliance (HCRA)$15,000
Funding body: Hunter Cancer Research Alliance (HCRA)
Funding body | Hunter Cancer Research Alliance (HCRA) |
---|---|
Project Team | Christopher Rowe, Hubert Hondermarck, Roger Smith, Shaun McGrath, Simon King, Marjorie Walker, John Attia |
Scheme | HCRA Implementation Flagship program |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2017 |
GNo | |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | N |
20162 grants / $376,248
Hunter New England Clinical Research Fellowship$351,248
Funding body: Hunter New England Health
Funding body | Hunter New England Health |
---|---|
Project Team | Christopher Rowe |
Scheme | Clinical Research Fellowship |
Role | Lead |
Funding Start | 2016 |
Funding Finish | 2019 |
GNo | |
Type Of Funding | Other Public Sector - State |
Category | 2OPS |
UON | N |
AVANT Doctors in Training Scholarship$25,000
Funding body: AVANT Mutual Group
Funding body | AVANT Mutual Group |
---|---|
Project Team | Christopher Rowe, Jonathan Paul, Jorge Tolosa, Roger Smith |
Scheme | Doctors in Training Scholarship Scheme |
Role | Lead |
Funding Start | 2016 |
Funding Finish | 2016 |
GNo | |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | N |
20151 grants / $20,000
NewDIAB: Understanding Type 1 Diabetes in Newcastle$20,000
Funding body: John Hunter Charitable Trust
Funding body | John Hunter Charitable Trust |
---|---|
Project Team | Christopher Rowe, Shamasunder Acharya, Lin Perry, Katie Wynne |
Scheme | John Hunter Charitable Trust Grant |
Role | Lead |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | |
Type Of Funding | Other Public Sector - State |
Category | 2OPS |
UON | N |
Research Supervision
Number of supervisions
Current Supervision
Commenced | Level of Study | Research Title | Program | Supervisor Type |
---|---|---|---|---|
2022 | Masters | Assessment Of Accuracy And Sensitivity Of Generic Health-Related Quality Of Life Tools In Thyroid Cancer Patients | M Philosophy (Medicine), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2022 | Masters | Development and Pilot Testing of a Decision Aid to Facilitate Shared Decision Making in Treatment of Low-Risk Thyroid Cancer | M Philosophy(Surgical Science), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2021 | Masters | Validation of Continuous Glucose Monitoring During Periods of Acute Glycaemic Variability in Pregnancy (After Betamethasone or During Labour) | M Philosophy (Medicine), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2021 | Masters | The Foundation for the Development of a Decision Aid to Facilitate Shared Decision Making in the Treatment of Low-Risk Thyroid Cancer | M Philosophy(Surgical Science), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
Research Collaborations
The map is a representation of a researchers co-authorship with collaborators across the globe. The map displays the number of publications against a country, where there is at least one co-author based in that country. Data is sourced from the University of Newcastle research publication management system (NURO) and may not fully represent the authors complete body of work.
Country | Count of Publications | |
---|---|---|
Australia | 37 | |
United Kingdom | 4 |
Dr Christopher Rowe
Position
Conjoint Senior Lecturer
School of Medicine and Public Health
College of Health, Medicine and Wellbeing
Contact Details
christopher.w.rowe@newcastle.edu.au | |
Link |